Challenges of Introducing New Biomarker Products for Neuropsychiatric Disorders into the Market

International Review of Neurobiology

Volumn 101, Issue , 2011, Pages 299-327

  Bahn, Sabine ^a,b   Noll, Richard ^c   Barnes, Anthony ^d   Schwarz, Emanuel ^a   Guest, Paul C ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c DESALES UNIVERSITY   (United States)

^d Rules Based Medicine   (United States)

Author keywords

Biomarkers; Diagnosis; Psychiatrists; Regulatory authorities; Schizophrenia

Indexed keywords

BIOLOGICAL MARKER;

BIOTECHNOLOGY; BLOOD ANALYSIS; BOOK; CLINICAL FEATURE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG RESEARCH; EARLY DIAGNOSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENOME ANALYSIS; GENOMICS; GOVERNMENT REGULATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MENTAL DISEASE; MOLECULAR DIAGNOSIS; NONHUMAN; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PSYCHIATRIC DIAGNOSIS; SCHIZOPHRENIA; SERODIAGNOSIS;

EID: 80055075586     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-387718-5.00012-2     Document Type: Chapter

References (123)

1. Agirbaşli M., Nguyen M.L., Win K., Kunselman A.R., Clark J.B., Myers J.L., Undar A. Inflammatory and hemostatic response to cardiopulmonary bypass in pediatric population: feasibility of seriological testing of multiple biomarkers. Artif. Organs 2010, 34:987-995.
2. Agius M., Shah S., Ramkisson R., Murphy S., Zaman R. Three year outcomes of an early intervention for psychosis service as compared with treatment as usual for first psychotic episodes in a standard community mental health team. Preliminary results. Psychiatr. Danub. 2007, 19:10-19.
3. Aisen P.S., Andrieu S., Sampaio C., Carrillo M., Khachaturian Z.S., Dubois B., Feldman H.H., Petersen R.C., Siemers E., Doody R.S., Hendrix S.B., Grundman M., et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology 2011, 76:280-286.
4. Alymani N.A., Smith M.D., Williams D.J., Petty R.D. Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation. Eur. J. Cancer 2010, 46:869-879.
5. Bagby R.M., Rogers R., Buis T., Nicholson R.A., Cameron S.L., Rector N.A., Schuller D.R., Seeman M.V. Detecting feigned depression and schizophrenia on the MMPI-2. J. Pers. Assess. 1997, 68:650-664.
6. Ball R.H., Caughey A.B., Malone F.D., Nyberg D.A., Comstock C.H., Saade G.R., Berkowitz R.L., Gross S.J., Dugoff L., Craigo S.D., Timor-Tritsch I.E., Carr S.R., et al. First- and second-trimester evaluation of risk for Down syndrome. Obstet. Gynecol. 2007, 110:10-17.
7. Bellmunt J., González-Larriba J.L., Prior C., Maroto P., Carles J., Castellano D., Mellado B., Gallardo E., Perez-Gracia J.L., Aguilar G., Villanueva X., Albanell J., et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann. Oncol. 2011, Mar 21 (Epub ahead of print).
8. Bertenshaw G.P., Yip P., Seshaiah P., Zhao J., Chen T.H., Wiggins W.S., et al. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 2008, 17:2872-2881.
9. Bhatta D., Christie G., Madrigal-González B., Blyth J., Lowe C.R. Holographic sensors for the detection of bacterial spores. Biosens. Bioelectron. 2007, 23:520-527.
10. Boja E.S., Jortani S.A., Ritchie J., Hoofnagle A.N., Tezak Z., Mansfield E., Keller P., Rivers R.C., Rahbar A., Anderson N.L., Srinivas P., Rodriguez H. The journey to regulation of protein-based multiplex quantitative assays. Clin. Chem. 2011, 57:560-567.
11. Bondy B. Genetics in psychiatry: are the promises met?. World J. Biol. Psychiatry 2011, 12:81-88.
12. Cheniaux E., Landeira-Fernandez J., Versiani M. The diagnoses of schizophrenia, schizoaffective disorder, bipolar disorder and unipolar depression: interrater reliability and congruence between DSM-IV and ICD-10. Psychopathology 2009, 42:293-298.
13. Clendenen T.V., Lundin E., Zeleniuch-Jacquotte A., Koenig K.L., Berrino F., Lukanova A., Lokshin A.E., Idahl A., Ohlson N., Hallmans G., Krogh V., Sieri S.A., et al. Circulating inflammation markers and risk of epithelial ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 2011, 20:799-810.
14. Cronin M., Sangli C., Liu M.L., Pho M., Dutta D., Nguyen A., Jeong J., Clark-Langone K.M., Watson D. Analytical validation of the OncotypeDX genomic test for recurence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin. Chem. 2007, 53:1084-1091.
15. Dauncey M.J., Bicknell R.J. Nutrition and neurodevelopment: mechanisms of developmental dysfunction and disease in later life. Nutr. Res. Rev. 1999, 12:231-253.
16. Davies L.M., Drummond M.F. The economic burden of schizophrenia. Psychiatric Bull. 1990, 14:522-525.
17. Desmedt C., Sperinde J., Piette F., Huang W., Jin X., Tan Y., Durbecq V., Larsimont D., Giuliani R., Chappey C., Buyse M., Winslow J., et al. Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. Diagn. Mol. Pathol. 2009, 18:22-29.
18. Dick D.M. Gene-environment interaction in psychological traits and disorders. Annu. Rev. Clin. Psychol. 2011, 7:383-409.
19. Dieterle F., Sistare F., Goodsaid F., Papaluca M., et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat. Biotechnol. 2010, 28:455-462.
20. DiMasi J.A., Faden L.B. Competitiveness in follow-on drug R&D: a race or imitation?. Nat. Rev. Drug Discov. 2011, 10:23-27.
21. Dohan F.C. Coeliac disease and schizophrenia. Lancet 1970, 1(7652):897-898.
22. Duan H., Fleming J., Pritchard D.K., Amon L.M., Xue J., Arnett H.A., et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum. 2008, 58:1465-1474.
23. Dunayevich E., Keck P.E. Prevalence and description of psychotic features in bipolar mania. Curr. Psychiatry Rep. 2000, 2:286-290.
24. Dynes J.B. Diabetes in schizophrenia and diabetes in nonpsychotic medical patients. Dis. Nerv. Syst. 1969, 30:341-344.
25. Ellington A.A., Kullo I.J., Bailey K.R., Klee G.G. Antibody-based protein multiplex platforms: technical and operational challenges. Clin. Chem. 2010, 56:186-193.
26. Ferrier I.N., Stanton B.R., Kelly T.P., Scott J. Neuropsychological function in euthymic patients with bipolar disorder. Br. J. Psychiatry 1999, 175:246-251.
27. Fleeman N., Dundar Y., Dickson R., Jorgensen A., Pushpakom S., McLeod C., Pirmohamed M., Walley T. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J. 2010, 11:1-14.
28. Fleischhacker W. Negative symptoms in patients with schizophrenia with special reference to the primary versus secondary distinction. Encéphale 2000, 26(Spec No 1):12-14.
29. Flood D.G., Marek G.J., Williams M. Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine. Biochem. Pharmacol. 2011, 81:1422-1434.
30. Follette W.C., Houts A.C. Models of scientific progress and the role of theory in taxonomy development: a case study of the DSM. J. Consult. Clin. Psychol. 1996, 64:1120-1132.
31. Gallien S., Duriez E., Domon B. Selected reaction monitoring applied to proteomics. J. Mass Spectrom. 2011, 46:298-312.
32. Gjertson C.K., Albertsen P.C. Use and assessment of PSA in prostate cancer. Med. Clin. North Am. 2011, 95:191-200.
33. Gonzalez-Pinto A., Gutierrez M., Mosquera F., Ballesteros J., Lopez P., Ezcurra J., Figuerido J.L., de Leon J. First episode in bipolar disorder: misdiagnosis and psychotic symptoms. J. Affect. Disord. 1998, 50:41-44.
34. Goodsaid F., Frueh F. Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 2006, 7:773-782.
35. Goodsaid F., Frueh F.W. Implementing the U.S. FDA guidance on pharmacogenomic data submissions. Environ. Mol. Mutagen. 2007, 48:354-358.
36. Guest P.C., Wang L., Harris L.W., Burling K., Levin Y., Ernst A., Wayland M.T., Umrania Y., Herberth M., Koethe D., van Beveren J.M., Rothermundt M., et al. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol. Psychiatry 2010, 15:118-119.
37. Guest P.C., Schwarz E., Krishnamurthy D., Harris L.W., Leweke F.M., Rothermundt M., van Beveren N.J., Spain M., Barnes A., Steiner J., Rahmoune H., Bahn S. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 2011, 36:1092-1096.
38. Gurbel P.A., Kreutz R.P., Bliden K.P., DiChiara J., Tantry U.S. Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. Am. Heart J. 2008, 155:56-61.
39. Hafner H., Maurer K. Early detection of schizophrenia: current evidence and future perspectives. World Psychiatry 2006, 5:130-138.
40. Hirschfeld R.M. Bipolar spectrum disorder: improving its recognition and diagnosis. J. Clin. Psychiatry 2001, 62(Suppl 14):5-9.
41. Howey J.E., Bennet W.M., Browning M.C., Jung R.T., Fraser C.G. Clinical utility of assays of glycosylated haemoglobin and serum fructosamine compared: use of data on biological variation. Diabet. Med. 1989, 6:793-796.
42. Hunter A.J. The Innovative Medicines Initiative: a pre-competitive initiative to enhance the biomedical science base of Europe to expedite the development of new medicines for patients. Drug Discov. Today 2008, 13:371-373.
43. Kabilan S., Marshall A.J., Sartain F.K., Lee M.C., Hussain A., Yang X., Blyth J., Karangu N., James K., Zeng J., Smith D., Domschke A., et al. Holographic glucose sensors. Biosens. Bioelectron. 2005, 20:1602-1610.
44. Kamel N., Compton C., Middelveld R., Higenbottam T., Dahlén S.E. The Innovative Medicines Initiative (IMI): a new opportunity for scientific collaboration between academia and industry at the European level. Eur. Respir. J. 2008, 31:924-926.
45. Kashshai D., Mate B. The effect of nicotinic acid on the temperature of the skin of patients with schizophrenia in different states. Zh. Nevropatol. Psikhiatr. Im. S S Korsakova 1961, 61:1688-1698.
46. Kato M., Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol. Psychiatry 2010, 15:473-500.
47. Keller W.R., Fischer B.A., Carpenter W.T. Revising the diagnosis of schizophrenia: where have we been and where are we going?. CNS Neurosci. Ther. 2011, 17:83-88.
48. Khristov V. Glucose clamping-a modern method for research on insulin secretion and resistance. Vutr. Boles. 1986, 25:32-39.
49. Klug T.L., Bast R.C., Niloff J.M., Knapp R.C., Zurawski V.R. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res. 1984, 44:1048-1053.
50. Knapp M., Mangalore R., Simon J. The global costs of schizophrenia. Schizophr. Bull. 2004, 30:279-293.
51. Koenig J.I., Kirkpatrick B., Lee P. Glucocorticoid hormones and early brain development in schizophrenia. Neuropsychopharmacology 2002, 27:309-318.
52. Kopec K.K., Bozyczko-Coyne D., Williams M. Target identification and validation in drug discovery: the role of proteomics. Biochem. Pharmacol. 2005, 69:1133-1139.
53. Kuriyama M., Wang M.C., Papsidero L.D., Killian C.S., Shimano T., Valenzuela L., Nishiura T., Murphy G.P., Chu T.M. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res. 1980, 40:4658-4662.
54. Lander E.S., Linton L.M., Birren B., Nusbaum C., et al. Initial sequencing and analysis of the human genome. Nature 2001, 409:860-921.
55. Laughren T.P. What's next after 50 years of psychiatric drug development: an FDA perspective. J. Clin. Psychiatry 2010, 71:1196-1204.
56. Lee S.P., Ataga K.I., Zayed M., Manganello J.M., Orringer E.P., Phillips D.R., et al. Phase I study of eptifibatide in patients with sickle cell anaemia. Br. J. Haematol. 2008, 139:612-620.
57. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
58. Lopez-Otin C., Overall C.M. Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell Biol. 2002, 3:509-519.
59. Lovatt A., Mason O., Brett C., Peters E. Psychotic-like experiences, appraisals, and trauma. J. Nerv. Ment. Dis. 2010, 198:813-819.
60. Macphail S.R. Clinical observations on the blood of the insane. Br. J. Psychiatry 1884, 30:378-389.
61. Marson B. ''Critical Path'' is on the road forward; FDA reports industry activity is high. Pink Sheet 2007, 69:29.
62. McGue M. When assessing twin concordance, use the probandwise not the pairwise rate. Schizophr. Bull. 1992, 18:171-176.
63. Millan E. The Value of the Schizophrenia Diagnostic Market. Masters of Business Administration Individual Project 2007, Judge Business School, Cambridge University, United Kingdom.
64. Mueller M., Martens L., Apweiler R. Annotating the human proteome: beyond establishing a parts list. Biochim. Biophys. Acta 2007, 1774:175-191.
65. Nakao M., Barrero R.A., Mukai Y., Motono C., Suwa M., Nakai K. Large-scale analysis of human alternative protein isoforms: pattern classification and correlation with subcellular localization signals. Nucleic Acids Res. 2005, 33:2355-2363.
66. Noll R. The blood of the insane. Hist. Psychiatry 2006, 17:395-418.
67. Noll R. American madness: the rise and fall of dementia praecox 2011, Harvard University Press, Cambridge.
68. Ovens J. Funding for accelerating drug development initiative critical. Nat. Rev. Drug Discov. 2006, 5:271.
69. Ozer J.S., Dieterle F., Troth S., Perentes E., Cordier A., Verdes P., Staedtler F., Mahl A., Grenet O., Roth D.R., Wahl D., Legay F., et al. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat. Biotechnol. 2010, 28:486-494.
70. Ozlu N., Akten B., Timm W., Haseley N., Steen H., Steen J.A. Phosphoproteomics. Wiley Interdiscip. Rev. Syst. Biol. Med. 2010, 2:255-276.
71. Pan S., Chen R., Aebersold R., Brentnall T.A. Mass spectrometry based glycoproteomics-from a proteomics perspective. Mol Cell Proteomics 2011, 10. R110.003251.
72. Pandey A. 'Genes were easy'-the launch of the Human Proteome Organization. Trends Genet. 2001, 17:250.
73. Pegram M.D., Pauletti G., Slamon D.J. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat. 1998, 52:65-77.
74. Pierre J.M. Deconstructing schizophrenia for DSM-V: challenges for clinical and research agendas. Clin. Schizophr. Relat. Psychoses 2008, 2:166-174.
75. Plymoth A., Hainaut P. Proteomics beyond proteomics: toward clinical applications. Curr. Opin. Oncol. 2011, 23:77-82.
76. Post R.M. The impact of bipolar depression. J. Clin. Psychiatry 2005, 66(Suppl. 5):5-10.
77. Poste G. Bring on the biomarkers. Nature 2011, 469:156-157.
78. Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752. International Schizophrenia Consortium.
79. Riedel M., Strassnig M., Schwarz M.J., Müller N. COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date. CNS Drugs 2005, 19:805-819.
80. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., Niederehe G., Thase M.E., Lavori P.W., Lebowitz B.D., McGrath P.J., Rosenbaum J.F., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR D report. Am. J. Psychiatry 2006, 163:1905-1917.
81. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 2003, 160:284-289.
82. Salokangas R.K., McGlashan T.H. Early detection and intervention of psychosis. A review. Nord. J. Psychiatry 2008, 62:92-105.
83. Sartain F.K., Yang X., Lowe C.R. Holographic lactate sensor. Anal. Chem. 2006, 78:5664-5670.
84. Satake K., Kanazawa G., Kho I., Chung Y.S., Umeyama K. A clinical evaluation of carbohydrate antigen 19-9 and carcinoembryonic antigen in patients with pancreatic carcinoma. J. Surg. Oncol. 1985, 29:15-21.
85. Scaglia F. The role of mitochondrial dysfunction in psychiatric disease. Dev. Disabil. Res. Rev. 2010, 16:136-143.
86. Schaffer D. A participant's observations: preparing DSM-IV. Can. J. Psychiatry 1996, 41:325-329.
87. Schanze A., Reulbach U., Scheuchenzuber M., Groschl M., Kornhuber J., Kraus T. Ghrelin and eating disturbances in psychiatric disorders. Neuropsychobiology 2008, 57:126-130.
88. Schlotz W., Phillips D.I. Fetal origins of mental health: evidence and mechanisms. Brain Behav. Immun. 2009, 23:905-916.
89. Schwarz E., Izmailov R., Spain M., Barnes A., Mapes J.P., Guest P.C., Rahmoune H., Pietsch S., Leweke F.M., Rothermundt M., Steiner J., Koethe D., et al. Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark. Insights 2010, 5:39-47.
90. Schwarz E., Guest P.C., Rahmoune H., Harris L.W., Wang L., Leweke F.M., Rothermundt M., Bogerts B., Koethe D., Kranaster L., Ohrmann P., Suslow T., et al. Identification of a biological signature for schizophrenia in serum. Mol. Psychiatry 2011, Apr 12 (Epub ahead of print).
91. Schwarz E., Guest P.C., Rahmoune H., Martins-de-Souza D., Niebuhr D.W., Weber N.S., Cowan D.N., Torrey E.F., Yolken R.H., Spain M., Barnes A., Bahn S. Identification of a blood-based biological signature in subjects with psychiatric disorders prior to clinical manifestation. World J Biol. Psychiatry 2011, (in press).
92. Shi J., Levinson D.F., Duan J., Sanders A.R., Zheng Y., Pe'er I., Dudbridge F., Holmans P.A., Whittemore A.S., Mowry B.J., Olincy A., Amin F., et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009, 460:753-757.
93. Spadoni L.R., Mclean R.B., Herrmann W.L. A rapid immunological test for the detection of early pregnancy. West. J. Surg. Obstet. Gynecol. 1964, 72:92-97.
94. Spelman L.M., Walsh P.I., Sharifi N., Collins P., Thakore J.H. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet. Med. 2007, 24:481-485.
95. Spitzer R.L., Williams J.B., Skodol A.E. DSM-III: the major achievements and an overview. Am. J. Psychiatry 1980, 137:151-164.
96. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., et al. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
97. Stein A., Mosca R., Aloy P. Three-dimensional modeling of protein interactions and complexes is going 'omics. Curr. Opin. Struct. Biol. 2011, 21:200-208.
98. Steiner J., Jacobs R., Panteli B., Brauner M., Schiltz K., Bahn S., Herberth M., Westphal S., Gos T., Walter M., Bernstein H.G., Myint A.M., et al. Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity. Eur. Arch. Psychiatry Clin. Neurosci. 2010, 260:509-518.
99. Strakowski S.M., Keck P.E., Arnold L.M., Collins J., Wilson R.M., Fleck D.E., Corey K.B., Amicone J., Adebimpe V.R. Ethnicity and diagnosis in patients with affective disorders. J. Clin. Psychiatry 2003, 64:747-754.
100. Swain A., Turton J., Scudamore C.L., Pereira I., Viswanathan N., Smyth R., Munday M., McClure F., Gandhi M., Sondh S., York M. Urinary biomarkers in hexachloro-1:3-butadiene-induced acute kidney injury in the female Hanover Wistar rat; correlation of α-glutathione S-transferase, albumin and kidney injury molecule-1 with histopathology and gene expression. J. Appl. Toxicol. 2011, 31:366-377.
101. Swanson B.N. Delivery of high-quality biomarker assays. Dis. Markers 2002, 18:47-56.
102. Szulc A., Galińska B., Konarzewska B., Gudel-Trochimowicz I., Popławska R. Immunological marker activity in first episode schizophrenic patients. Pol. Merkur. Lekarski 2001, 10:450-452.
103. Tan E.V., Lowe C.R. Holographic enzyme inhibition assays for drug discovery. Anal. Chem. 2009, 81:7579-7589.
104. Tan D.S., Thomas G.V., Garrett M.D., Banerji U., de Bono J.S., Kaye S.B., Workman P. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J. 2009, 15:406-420.
105. Taube S.E., Clark G.M., Dancey J.E., McShane L.M., Sigman C.C., Gutman S.I. A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J. Natl. Cancer Inst. 2009, 101:1453-1463.
106. Thomas P. The many forms of bipolar disorder: a modern look at an old illness. J. Affect. Disord. 2004, 79(Suppl 1):S3-S8.
107. Torrey E.F. Are we overestimating the genetic contribution to schizophrenia?. Schizophr. Bull. 1992, 18:159-170.
108. Truglia J.A., Livingston J.N., Lockwood D.H. Insulin resistance: receptor and post-binding defects in human obesity and non-insulin-dependent diabetes mellitus. Am. J. Med. 1985, 79:13-22.
109. Tsuang M.T. Heterogeneity of schizophrenia. Biol. Psychiatry 1975, 10:465-474.
110. Tsuang M. Schizophrenia: genes and environment. Biol. Psychiatry 2000, 47:210-220.
111. Tsuang M.T., Perkins K., Simpson J.C. Physical diseases in schizophrenia and affective disorder. J. Clin. Psychiatry 1983, 44:42-46.
112. Vaddadi K.S. Niacin flushing and schizophrenia. Med. Hypotheses 1981, 7:599-600.
113. van Nimwegen L.J., Storosum J.G., Blumer R.M., Allick G., Venema H.W., de Haan L., Becker H., van Amelsvoort T., Ackermans M.T., Fliers E., Serlie M.J., Sauerwein H.P. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J. Clin. Endocrinol. Metab. 2008, 93:572-577.
114. van Venrooij J.A., Fluitman S.B., Lijmer J.G., Kavelaars A., Heijnen C.J., Westenberg H.G., Kahn R.S., Gispen-de Wied C.C., van Venrooij J.A., Fluitman S.B., Lijmer J.G., Kavelaars A., et al. Impaired neuroendocrine and immune response to acute stress in medication-naive patients with a first episode of psychosis. Schizophr. Bull. 2010, Jun 17 (Epub ahead of print).
115. Venkatasubramanian G., Chittiprol S., Neelakantachar N., Shetty T.K., Gangadhar B.N. A longitudinal study on the impact of antipsychotic treatment on serum leptin in schizophrenia. Clin. Neuropharmacol. 2010, 33:288-292.
116. Ventner J.C., Adams M.D., Myers E.W., Li P.W., et al. The sequence of the human genome. Science 2001, 291:1304-1351.
117. Wakefield J.C. Misdiagnosing normality: Psychiatry's failure to address the problem of false positive diagnoses of mental disorder in a changing professional environment. J. Ment. Health 2010, 19:337-351.
118. Wilson D.W., Douglass A.B. Niacin skin flush is not diagnostic of schizophrenia. Biol. Psychiatry 1986, 21:974-977.
119. Wu E.Q., Birnbaum H.G., Shi L., Ball D.E., Kessler R.C., Moulis M., Aggarwal J. The economic burden of schizophrenia in the United States in 2002. J. Clin. Psychiatry 2005, 66:1122-1129.
120. Yang J., Wang B.J., Ding M., Pang H., Sun X.F., Li Z.J. The relationship between SNP of cholecystokinin gene and certain mental status and its forensic significance. Fa Yi Xue Za Zhi 2008, 24:284-287.
121. Yap H.L. Early psychosis intervention. Singapore Med. J. 2010, 51:689-693.
122. Yolken R.H., Dickerson F.B., Fuller Torrey E. Toxoplasma and schizophrenia. Parasite Immunol. 2009, 31:706-715.
123. Zhang Z., Chan D.W. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol. Biomarkers Prev. 2010, 19:2995-2999.